Last quarter (Q ), PharmaCyte Biotech's total revenue was $―, a decrease of ― from the same quarter last year. In Q, PharmaCyte Biotech's net income was $-2.26M. See PharmaCyte Biotech’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Apr 23	Apr 22	Apr 21	Apr 20	Apr 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 1.93M	$ 6.46M	$ 4.39M	$ 3.62M	$ 3.83M	$ 4.10M
Operating Income	$ -4.24M	$ -6.46M	$ -4.39M	$ -3.62M	$ -3.83M	$ -4.10M
Net Non Operating Interest Income Expense	$ 2.41M	$ 1.94M	$ 157.14K	$ 72.93K	$ -453.00	$ 0.00
Other Income Expense	$ -678.38K	$ -202.00K	$ 4.28K	$ 1.19K	$ -40.00	$ 33.40K
Pretax Income	$ -1.16M	$ -4.32M	$ -4.24M	$ -3.55M	$ -3.83M	$ -4.07M
Tax Provision	-	$ -906.36K	$ -890.22K	$ -1.89K	-	-
Earnings From Equity Interest Net Of Tax	-	$ 5.88K	-	-	-	-
Net Income Common Stockholders	$ -6.53M	$ -4.32M	$ -4.24M	$ -3.55M	$ -3.83M	$ -4.07M
Basic EPS	$ -0.58	$ -0.22	$ -0.27	$ -2.45	$ -4.23	-
Diluted EPS	$ -0.58	$ -0.22	$ -0.27	$ -2.45	$ -4.23	-
Basic Average Shares	$ 40.36M	$ 19.49M	$ 15.52M	$ 1.45M	$ 904.26K	-
Diluted Average Shares	$ 40.36M	$ 19.49M	$ 15.52M	$ 1.45M	$ 904.26K	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 1.93M	$ 6.46M	$ 4.39M	$ 3.62M	$ 3.83M	$ 4.10M
Net Income From Continuing And Discontinued Operation	$ -1.16M	$ -4.32M	$ -4.24M	$ -3.55M	$ -3.83M	$ -4.07M
Normalized Income	$ -389.47K	$ -5.22M	-	-	$ -3.83M	$ -4.07M
Interest Expense	-	-	-	-	$ 453.00	$ 0.00
EBIT	$ -1.79M	$ -4.32M	$ -4.24M	$ -3.62M	$ -3.83M	$ -4.07M
EBITDA	$ -393.40K	$ -4.32M	$ -4.24M	$ -3.62M	$ -3.83M	$ -4.07M

Currency in USD

PharmaCyte Biotech Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing